Malignant Conjunctival Melanoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: MLG142 MIFTS: 37	Malignant Conjunctival Melanoma Categories: Cancer diseases, Neuronal diseases, Rare diseases, Skin diseases
Genes Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Malignant Conjunctival Melanoma

MalaCards integrated aliases for Malignant Conjunctival Melanoma:

Name: Malignant Conjunctival Melanoma ¹² ¹⁵

Conjunctival Melanoma ¹² ²⁰ ¹⁷

Malignant Melanoma of Conjunctiva ¹² ⁷¹

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Neuronal diseases Skin diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:1751

NCIt ⁵⁰ C4550

SNOMED-CT ⁶⁷ 255004001

EFO ¹⁷ EFO_1000204

UMLS ⁷¹ C0346360

Sources

Summaries for Malignant Conjunctival Melanoma

MalaCards based summary : Malignant Conjunctival Melanoma, also known as conjunctival melanoma, is related to conjunctival pigmentation and ocular melanoma. An important gene associated with Malignant Conjunctival Melanoma is MIR518A1 (MicroRNA 518a-1), and among its related pathways/superpathways are Toll-like Receptor Signaling Pathway and Development Angiotensin activation of ERK. The drugs Melphalan and Pancrelipase have been mentioned in the context of this disorder. Affiliated tissues include lymph node, liver and eye.

Sources

Related Diseases for Malignant Conjunctival Melanoma

Diseases related to Malignant Conjunctival Melanoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 93)

#	Related Disease	Score	Top Affiliating Genes
1	conjunctival pigmentation	30.6	MLANA IFNA2
2	ocular melanoma	30.5	NRAS GNAQ GNA11
3	ocular cancer	30.1	MLANA GNAQ GNA11
4	mucosal melanoma	30.1	NRAS IFNA2 GNAQ GNA11
5	conjunctival nevus	29.8	NRAS MLANA HRAS GNAQ
6	skin melanoma	29.8	NRAS MLANA IFNA2 HRAS GNAQ GNA11
7	nasal cavity cancer	29.6	MLANA HRAS
8	melanoma, uveal	29.6	NRAS MLANA MIR501 HRAS GNAQ GNA11
9	nodular malignant melanoma	29.5	NRAS MLANA HRAS GNAQ GNA11
10	melanoma	29.5	NRAS MLANA MIR302D IFNA2 HRAS GNAQ
11	spitzoid melanoma	29.3	NRAS MLANA HRAS GNAQ GNA11
12	ovarian melanoma	10.3	NRAS MLANA
13	rare tumor	10.3
14	sensory organ benign neoplasm	10.3	NRAS MLANA
15	phakomatosis cesioflammea	10.3	GNAQ GNA11
16	epithelioid cell melanoma	10.3	MLANA GNA11
17	hypocalciuric hypercalcemia, familial, type ii	10.2	GNAQ GNA11
18	melanomatosis	10.2	NRAS MLANA GNAQ
19	weber syndrome	10.1	GNAQ GNA11
20	meningeal melanocytoma	10.1	MLANA GNAQ GNA11
21	hypomelanosis of ito	10.1	NRAS GNAQ GNA11
22	mongolian spot	10.1	MLANA GNAQ GNA11
23	limbal stem cell deficiency	10.1
24	acneiform dermatitis	10.1	NRAS HRAS
25	lentigines	10.1
26	xeroderma pigmentosum, variant type	10.1
27	severe combined immunodeficiency	10.1
28	core binding factor acute myeloid leukemia	10.0	NRAS HRAS
29	meningeal melanoma	10.0	NRAS MLANA GNAQ GNA11
30	oculoectodermal syndrome	10.0	NRAS HRAS
31	malignant leptomeningeal tumor	10.0	NRAS MLANA GNAQ GNA11
32	large intestine adenocarcinoma	10.0	NRAS HRAS
33	nasal cavity adenocarcinoma	10.0	MLANA HRAS
34	melanocytic nevus syndrome, congenital	10.0	NRAS HRAS
35	orbit rhabdomyosarcoma	10.0	NRAS MLANA IFNA2 GNAQ
36	retinal detachment	10.0
37	retinoblastoma	10.0
38	ptosis	10.0
39	conjunctival squamous cell carcinoma	10.0
40	neurofibromatosis	10.0
41	keratoconjunctivitis	10.0
42	lentigo maligna melanoma	10.0
43	squamous cell carcinoma	10.0
44	amelanotic melanoma	10.0
45	benign struma ovarii	10.0	NRAS HRAS
46	nevus, epidermal	9.9	NRAS HRAS GNAQ
47	vulvar disease	9.9	NRAS HRAS
48	differentiated thyroid carcinoma	9.9	NRAS HRAS EIF1AX
49	thyroid gland follicular carcinoma	9.8	NRAS HRAS EIF1AX
50	malignant anus melanoma	9.8	NRAS MLANA HRAS GNA11

Graphical network of the top 20 diseases related to Malignant Conjunctival Melanoma:

Sources

Symptoms & Phenotypes for Malignant Conjunctival Melanoma

Sources

Drugs & Therapeutics for Malignant Conjunctival Melanoma

Drugs for Malignant Conjunctival Melanoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 22)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Melphalan

Approved

Phase 2

148-82-3

4053 460612

Synonyms:

(2s)-2-amino-3-(4-[bis(2-chloroethyl)amino]phenyl)propanoic acid

(2S)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoic acid

148-82-3

3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine

3-(p-(Bis(2-chloroethyl)amino)phenyl)-L-alanine

3025 c.b

3025 C.B.

3223-07-2

3-p-(Di(2-chloroethyl)amino)-phenyl-L-alanine

4-(Bis(2-chloroethyl)amino)-L-phenylalanine

4-(Bis(2-chloroethyl)amino)phenylalanine

4-[Bis(2-chloroethyl)amino]-L-phenylalanine

4-[Bis-(2-chloroethyl)amino]-L-phenylalanine

4-14-00-01689 (Beilstein Handbook Reference)

AC1LA2OE

Alanine Nitrogen Mustard

Alkeran

ALKERAN (TN)

AmbotzHAA1563

At-290

AY3360000

BIDD:GT0044

BRD-K87827419-001-02-8

BRN 2816456

BSPBio_002407

C13H18Cl2N2O2

CB 3025

CB-3025

CCRIS 374

CHEBI:165415

CHEBI:28876

CHEMBL852

CID460612

D00369

DivK1c_000653

EINECS 205-726-3

HMS2090B09

HMS2091B16

HMS502A15

HSDB 3234

IDI1_000653

KBio1_000653

KBio2_000877

KBio2_003445

KBio2_006013

KBio3_001627

KBioGR_001284

KBioSS_000877

L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine

L-3-(para-(Bis(2-chloroethyl)amino)phenyl)alanine

Levofalan

Levofolan

Levopholan

L-PAM

L-Phenylalanine mustard

LS-15868

LS-865

L-Sarcolysin

L-Sarcolysine

L-Sarkolysin

M2011_SIGMA

Medphalan

Melfalan

Melfalano

Melfalano [INN-Spanish]

melphalan

Melphalan

Melphalan (JP15/USP/INN)

MELPHALAN (SEE ALSO TRANSGENIC MODEL EVALUATION (MELPHALAN))

Melphalan [USAN:INN:BAN:JAN]

Melphalanum

Melphalanum [INN-Latin]

Mephalan

Merphalan

MLS001333666

MLS002153368

MolPort-003-665-535

Mustard, phenylalanine

NCGC00090757-01

NCGC00090757-02

NCGC00090757-03

NCI-C04853

NINDS_000653

NIOSH/AY3360000

NSC 241286

NSC 8806

NSC241286

NSC8806

NSC-8806

p-Bis(b-chloroethyl)aminophenylalanine

p-Bis(beta-chloroethyl)aminophenylalanine

p-Bis(β-chloroethyl)aminophenylalanine

p-Di-(2-chloroethyl)amino-L-phenylalanine

Phenylalanine mustard

phenylalanine nitrogen mu stard

Phenylalanine nitrogen mustard

p-L-Sarcolysin

p-L-sarcolysine

p-N,N-bis(2-chloroethyl)amino-L-phenylalanine

p-N,N-Bis(2-chloroethyl)amino-L-phenylalanine

p-N-Bis(2-chloroethyl)amino-L-phenylalanine

p-N-di(chloroethyl)aminophenylala nine

p-N-Di(chloroethyl)aminophenylalanine

Prestwick_1006

RCRA waste no. U150

Rcra waste number U150

Sarcolysine

Sarkolysin

SK-15673

SMP2_000174

SMR000058720

SPBio_000287

Spectrum_000397

SPECTRUM1500382

Spectrum2_000074

Spectrum3_000684

Spectrum4_000882

Spectrum5_001601

TL8001065

TRANSGENIC LEP (MELPHALAN) (SEE ALSO MELPHALAN)

TRANSGENIC MODEL EVALUATION (MELPHALAN)

UNII-Q41OR9510P

Pancrelipase

Approved, Investigational

Phase 2

53608-75-6

Cyclophosphamide

Approved, Investigational

Phase 2

50-18-0, 6055-19-2

2907

Synonyms:

(-)-Cyclophosphamide

(+-)-Cyclophosphamide

(+,-)-2-(Bis(2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate

(RS)-Cyclophosphamide

1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine

1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin

2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide

4-Hydroxy-cyclophosphan-mamophosphatide

50-18-0

60007-95-6

6055-19-2 (monohydrate)

75526-90-8

AC1L1EQQ

AI3-26198

Anhydrous cyclophosphamide

Anhydrous, cyclophosphamide

ASTA

Asta B 518

ASTA B518

B 518

B-518

bis(2-Chloroethyl)phosphami de cyclic propanolamide

bis(2-Chloroethyl)phosphamide cyclic propanolamide ester

Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester

BRN 0011744

BSPBio_002099

C 0768

C07888

C7H15Cl2N2O2P

CB 4564

CB-4564

CCRIS 188

CHEBI:4027

CHEMBL32520

CHEMBL88

Ciclofosfamida

Ciclofosfamida [INN-Spanish]

Ciclofosfamide

Ciclophosphamide

Ciclophosphamide [INN]

CID2907

Clafen

Claphene

CPA

CTX

Cycloblastin

Cyclophosphamid

cyclophosphamide

Cyclophosphamide

Cyclophosphamide (anhydrous form)

Cyclophosphamide (anhydrous)

Cyclophosphamide (INN)

Cyclophosphamide (TN)

Cyclophosphamide anhydrous

Cyclophosphamide monohydrate

Cyclophosphamide Monohydrate

Cyclophosphamide Sterile

Cyclophosphamide, (+-)-Isomer

Cyclophosphamide, (R)-isomer

Cyclophosphamide, (S)-isomer

Cyclophosphamides

Cyclophosphamidum

Cyclophosphamidum [INN-Latin]

Cyclophosphan

Cyclophosphane

Cyclophosphanum

Cyclophosphoramide

Cyclostin

Cyklofosfamid

Cyklofosfamid [Czech]

Cytophosphan

Cytophosphane

Cytoxan

Cytoxan (TN)

Cytoxan Lyoph

D,L-Cyclophosphamide

D07760

DB00531

DivK1c_000246

EINECS 200-015-4

Endoxan

Endoxan R

Endoxana

Endoxanal

Endoxan-Asta

Endoxane

Enduxan

EU-0100238

Genoxal

Hexadrin

HMS2090A12

HSDB 3047

IDI1_000246

KBio1_000246

KBio2_001338

KBio2_003906

KBio2_006474

KBio3_001319

KBioGR_000888

KBioSS_001338

Lopac0_000238

Lopac-C-0768

LS-1302

LS-99787

Lyophilized Cytoxan

Mitoxan

MolPort-001-783-420

Monohydrate, cyclophosphamide

N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide

N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide

NCGC00015209-01

NCGC00015209-03

NCGC00015209-06

NCGC00091741-02

NCGC00091741-03

NCI60_002097

NCI-C04900

Neosar

NINDS_000246

NSC 26271

NSC26271

NSC-26271

NSC273033

NSC273034

Occupation, cyclophosphamide exposure

Procytox

RCRA waste no. U058

Rcra waste number U058

Rcra Waste Number U058

Revimmune

S1217_Selleck

Semdoxan

Sendoxan

Senduxan

SK 20501

SPBio_001071

Spectrum_000858

Spectrum2_001146

Spectrum3_000370

Spectrum4_000304

Spectrum5_000795

STK177249

STOCK2S-91217

UNII-6UXW23996M

WLN: T6MPOTJ BO BN2G2G

Zyklophosphamid

Zyklophosphamid [German]

Lenalidomide

Approved

Phase 2

191732-72-6

216326

Synonyms:

191732-72-6

1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline

1-oxo-2-(2,6-Dioxopiperidin-3-yl)-4-aminoisoindoline

3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione

3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione

3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione

3-(7-Amino-3-oxo-1H-isoindol-2-yl)-piperidine-2,6-dione

346670-73-3

443912-14-9

AC1L50II

AC-914

AKOS005146276

ALBB-015321

Bio-0168

C467567

CC 5013

CC5013

CC-5013

CC-5013, Revlimid, Lenalidomide

CDC 501

CDC-501

CDC-5013

Celgene brand of lenalidomide

Celgene brand OF lenalidomide

CHEMBL848

CID216326

D04687

DB00480

EC-000.2340

ENMD-0997

I06-0831

IMID-1

IMiD3

IMiD3 cpd

IMiD3 CPD

IMID-5013

Lenalidomida

lenalidomide

Lenalidomide

Lenalidomide (USAN/INN)

Lenalidomide [USAN]

LS-184040

MolPort-003-848-370

NCGC00167491-01

NSC747972

Revamid

Revimid

Revlimid

Revlimid (Celgene)

Revlimid (TN)

S1029_Selleck

STK639603

Thalidomide analog CC-5013

UNII-F0P408N6V4

Sunitinib

Approved, Investigational

Phase 2

341031-54-7, 557795-19-4

5329102

Synonyms:

(2S)-2-hydroxybutanedioic acid

1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)

326914-13-0

341031-54-7

5-(5-FLUORO-2-OXO-1,2-DIHYDRO-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID (2-DIETHYLAMINO-ETHYL)-AMIDE

5-(5-Fluoro-2-oxo-1,2-dihydroindolylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide

557795-19-4

AC1NS62J

AC1O5CMQ

AKOS005145765

Butanedioic acid, hydroxy-, (2S)-, compd. with N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1)

CHEBI:38940

CHEBI:550864

CHEMBL1567

CHEMBL535

CID5329102

CID6456015

D06402

D08552

DB01268

DB07417

EN002687

FT-0083555

FT-0083556

I01-1229

K00588a

KS-5022

LS-186078

LS-187023

LS-187648

MolPort-003-986-763

N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-hydroxybutanedioate

N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide

N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide

NCGC00164631-01

NSC736511

NSC750690

PDGF TK antagonist

PHA-290940AD

PNU-290940AD

S1042_Selleck

ST51053712

SU 011248

SU 11248

SU010398

SU-010398

Su-011248

SU011248

SU011248 L-malate salt

SU-011248 L-malate salt

SU11248

SU-11248

SU-11248 L-malate salt

SU-11248J

SU-12662

Sunitanib

sunitinib

Sunitinib

Sunitinib (free base)

Sunitinib (INN)

Sunitinib malate

Sunitinib malate (JAN/USAN)

Sunitinib malate [USAN]

sunitinibum

Sunitinibum

Sutent

Sutent (TN)

Sutent, SU-11248

TL8002546

UNII-LVX8N1UT73

UNII-V99T50803M

Pancreatic Polypeptide

Investigational

Phase 2

59763-91-6

pancreatin

Phase 2

Immunosuppressive Agents

Phase 2

Immunologic Factors

Phase 2

Antirheumatic Agents

Phase 2

Protein Kinase Inhibitors

Phase 2

Alkylating Agents

Phase 2

Angiogenesis Inhibitors

Phase 2

Sargramostim

Approved, Investigational

Phase 1

123774-72-1, 83869-56-1

Synonyms:

123774-72-1

D05803

Leukine

Leukine (TN)

Recombinant human granulocyte-macrophage colony stimulating factor

rGM-CSF

rHu GM-CSF

Sargramostim

Sargramostim (genetical recombination)

Sargramostim (genetical recombination) (JAN)

Sargramostim (USAN/INN)

Molgramostim

Investigational

Phase 1

99283-10-0

Imatinib Mesylate

Phase 1

220127-57-1

123596

Vaccines

Phase 1

Freund's Adjuvant

Phase 1

Adjuvants, Immunologic

Phase 1

CPG-oligonucleotide

Phase 1

Liver Extracts

Early Phase 1

Cola

Early Phase 1

Interventional clinical trials:

#	Name	Status	NCT ID	Phase	Drugs
1	A Phase II Study Of Hepatic Arterial Infusion Of Melphalan With Venous Filtration Via Peripheral Hepatic Perfusion (PHP) For Unresectable Primary And Metastatic Cancers Of The Liver	Completed	NCT00096083	Phase 2	isolated perfusion;melphalan
2	A Phase II Study of Combination Oral CC-5013 Lenalidomide (Revlimid™), Oral Sunitinib (Sutent™) and Low Dose Oral Metronomic Cyclophosphamide for the Treatment of Stage IV Ocular Melanoma	Terminated	NCT00482911	Phase 2	cyclophosphamide;lenalidomide;sunitinib malate
3	Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib Mesylate in Patient With Rare Tumor (Phase I Study)	Completed	NCT01046487	Phase 1	Imatinib mesylate, Cyclophosphamide (Dosing level 1 );Imatinib mesylate, Cyclophosphamide (Dosing level 2);Imatinib mesylate, Cyclophosphamide (Dosing level 3)
4	A Multipeptide Vaccine in Melanoma Patients With Evaluation of the Injection Site Microenvironment	Completed	NCT00705640	Phase 1
5	Safety and Immunogenicity of Vaccination With Multi-Epitope Peptide Vaccine Containing MART-1, gp100, and Tyrosinase Peptides Given With the Combination of GMCSF and CpG Oligonucleotide (CpG 7909) in ISA-Oil Adjuvant for Patients With Recurrent Inoperable Stage III or Stage IV Melanoma	Completed	NCT00471471	Phase 1
6	Sequential Administration of Cryoablation and Cyclophosphamide for Advanced Solid Epithelial Cancer	Terminated	NCT00499733	Early Phase 1	cyclophosphamide

Search NIH Clinical Center for Malignant Conjunctival Melanoma

Sources

Genetic Tests for Malignant Conjunctival Melanoma

Sources

Anatomical Context for Malignant Conjunctival Melanoma

MalaCards organs/tissues related to Malignant Conjunctival Melanoma:

⁴⁰

Lymph Node, Liver, Eye, Skin, Breast, Testis

Sources

Publications for Malignant Conjunctival Melanoma

Articles related to Malignant Conjunctival Melanoma:

(show top 50) (show all 509)

#	Title	Authors	PMID	Year
1	Conjunctival and uveal melanoma: Survival and risk factors following orbital exenteration. ⁶¹	Baum SH...Mohr C	33573425	2021
2	m6A RNA hypermethylation-induced BACE2 boosts intracellular calcium release and accelerates tumorigenesis of ocular melanoma. ⁶¹	He F...Jia R	33601055	2021
3	Giant conjunctival melanoma in a paranoid schizophrenic man: A case report. ⁶¹	Supit T...Najatullah	33552501	2021
4	Indocyanine Green Angiographic Assessment of Conjunctival Melanocytic Disorders. ⁶¹	Palme C...Steger B	33591034	2021
5	Management of conjunctival melanoma with local excision and adjuvant brachytherapy. ⁶¹	Brouwer NJ...Luyten GPM	32332870	2021
6	Orbital exenteration for conjunctival melanoma: comparison of long-term outcome between individualised and conventional techniques. ⁶¹	Ma R...Qian J	33608640	2021
7	Secondary orbital exenteration for conjunctival melanoma: A study of 25 cases. ⁶¹	Lemaitre S...Desjardins L	33573797	2021
8	Conjunctival Melanoma Treated With Complete Circumferential Peripheral and Deep Margin Assessment ("Slow Mohs") Surgery. ⁶¹	Osemwota O...Council ML	31851016	2021
9	Immune Checkpoint Inhibitor Therapy as an Eye-Preserving Treatment for Locally Advanced Conjunctival Melanoma. ⁶¹	Hong BY...Esmaeli B	32618825	2021
10	Conjunctival melanoma: A 20-year survey in a comprehensive medical center. ⁶¹	Chen PY...Tsai YJ	32417175	2021
11	In-vivo imaging for assessing tumor growth in mouse models of ocular melanoma. ⁶¹	Zaks O...Aharoni-Simon M	33406396	2021
12	Interdisciplinary Surveillance of Ocular Melanomas: Experiences in a German Tertiary Centre. ⁶¹	Mor JM...Heindl LM	33242884	2021
13	Surveillance of patients with conjunctival melanoma in German-speaking countries: A multinational survey of the German dermatologic cooperative oncology group. ⁶¹	Wessely A...German Dermatologic Cooperative Oncology Group (DeCOG, committee ocular melanoma)	33279851	2021
14	Efficacy of immune checkpoint inhibitors in different types of melanoma. ⁶¹	Rossi E...Tortora G	32663057	2021
15	Genetics of Ocular Melanoma: Insights into Genetics, Inheritance and Testing. ⁶¹	van Poppelen NM...Kili? E	33396957	2020
16	F-18 fluorodeoxyglucose positron emission tomography/computed tomography in conjunctival melanoma with recurrence. ⁶¹	Jain A...Singh A	33380688	2020
17	Genomic and transcriptomic landscape of conjunctival melanoma. ⁶¹	Cisarova K...Rivolta C	33383577	2020
18	Current Management of Conjunctival Melanoma Part 2: Treatment and Future Directions. ⁶¹	Koc I...Kiratli H	33389937	2020
19	The molecular profile of mucosal melanoma. ⁶¹	Mikkelsen LH...Heegaard S	33156594	2020
20	Conjunctival Melanoma: Outcomes based on the American Joint Committee on Cancer Clinical Classification (8th Edition) of 425 Patients at a Single Ocular Oncology Center. ⁶¹	Shields CL...Shields JA	33306519	2020
21	Conjunctival melanoma: Risk factors for recurrent or new tumor in 540 patients at a single ocular oncology center. ⁶¹	Vaidya S...Shields CL	33176471	2020
22	PD-L1 Expression in 65 Conjunctival Melanomas and Its Association with Clinical Outcome. ⁶¹	Lassalle S...Hofman P	33266349	2020
23	The natural history of conjunctival naevi in children and adolescents. ⁶¹	Negretti GS...Cohen VML	33199866	2020
24	Conjunctival Melanoma with Ipsilateral, Non-Contiguous Eyelid Involvement: A Case Report and Comprehensive Review of the Literature. ⁶¹	Roelofs KA...Cohen VML	33123526	2020
25	Current Management of Conjunctival Melanoma Part 1: Clinical Features, Diagnosis and Histopathology. ⁶¹	Koc I...Kiratli H	33342197	2020
26	Orbital exenteration and conjunctival melanoma: a 14-year study at the Jules Gonin Eye Hospital. ⁶¹	Martel A...Hamedani M	31959885	2020
27	Transcriptional characterization of conjunctival melanoma identifies the cellular tumor microenvironment and prognostic gene signatures. ⁶¹	Wolf J...Lange CAK	33046735	2020
28	Conjunctival melanoma: Opportune detection and resolution of a fast-growing conjunctival lesion. ⁶¹	Vazquez-Romo KA...Ramos-Betancourt N	32620413	2020
29	Conjunctival melanoma treatment outcomes in 288 patients: a multicentre international data-sharing study. ⁶¹	Jain P...American Joint Committee on Cancer Ophthalmic Oncology Task Force	32892167	2020
30	Conjunctival Melanoma: Features and Outcomes Based on the Fitzpatrick Skin Type in 540 Patients at a Single Ocular Oncology Center. ⁶¹	Shields CL...Shields JA	32134771	2020
31	Clinical treatment options for early-stage and advanced conjunctival melanoma. ⁶¹	Zeng Y...Wu F	32980421	2020
32	Anterior Segment OCTA of Melanocytic Lesions of the Conjunctiva and Iris. ⁶¹	Brouwer NJ...Jager MJ	32926848	2020
33	First case of melanoma-associated retinopathy with conjunctival melanoma. ⁶¹	Evoy F...Lafortune J	32093922	2020
34	Conjunctival Melanoma Angiotropic Microsatellitosis: A Mechanism of Local Extravascular Migratory Metastasis. ⁶¹	Echegaray JJ...Singh AD	33005619	2020
35	Mascara deposits in an anophthalmic socket mimicking a conjunctival melanoma. ⁶¹	Martel A...Nahon-Esteve S	32811658	2020
36	Lacrimal drainage apparatus melanoma remotely following treatment and resolution of conjunctival melanoma. ⁶¹	Peck T...Rabinowitz M	32811269	2020
37	Invasive conjunctival melanoma mimicking ocular surface squamous neoplasia: a case series. ⁶¹	Gallo B...Sagoo MS	32675060	2020
38	Extensive conjunctival melanoma successfully treated with surgical resection and pre- and postoperative topical mitomycin C. ⁶¹	Mazzini C...Giansanti F	32674607	2020
39	Conjunctival Melanoma: Outcomes Based on Age at Presentation in 629 Patients at a Single Ocular Oncology Center. ⁶¹	Dalvin LA...Shields CL	32740010	2020
40	Molecular biology in conjunctival melanoma and the relationship to mucosal melanoma. ⁶¹	Mikkelsen LH	32749776	2020
41	Genetic Biomarkers in Melanoma of the Ocular Region: What the Medical Oncologist Should Know. ⁶¹	Bol KF...Svane IM	32718045	2020
42	[Personalized medicine in the treatment of periocular tumors : Targeted treatment and use of immune checkpoint inhibitors]. ⁶¹	Rokohl AC...Heindl LM	31938823	2020
43	Conjunctival Melanoma: Current Treatments and Future Options. ⁶¹	Grimes JM...Marr BP	31965542	2020
44	Image Analysis of 3D Conjunctival Melanoma Cell Cultures Following Electrochemotherapy. ⁶¹	Fiorentzis M...Coupland SE	32545782	2020
45	Controlling Conjunctival Melanoma-To Infinity and Beyond. ⁶¹	Shields CL...Orloff M	32215607	2020
46	Incidence and Survival of Patients With Conjunctival Melanoma in Europe. ⁶¹	Virgili G...RARECAREnet Working Group	32215588	2020
47	Conjunctival melanoma in an African American man. ⁶¹	Oh DJ...Kanu LN	32140618	2020
48	Intradural Extramedullary Metastatic Conjunctival Malignant Melanoma. ⁶¹	Cho KT...Lee K	32217182	2020
49	Primary Conjunctival Pigmented Basal Cell Carcinoma with Increased Numbers of Intra-Tumour Melanocytes, Mimicking Melanoma: A Case Report and Review of the Literature. ⁶¹	Mudhar HS...Hoque F	32509761	2020
50	Delayed Onset Scleromalacia and Conjunctival Bleb Formation Following Intraoperative Mitomycin C Application during Conjunctival Melanoma Excision. ⁶¹	Ahmed SN...Nanavaty MA	32384819	2020

Sources

Genes for Malignant Conjunctival Melanoma

Genes related to Malignant Conjunctival Melanoma (0 elite genes):

(show all 16)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	MIR518A1	MicroRNA 518a-1	RNA Gene	10.74	DISEASES inferred ¹⁵ ¹⁵
2	MIR501	MicroRNA 501	RNA Gene	9.3	DISEASES inferred ¹⁵ ¹⁵
3	NRAS	NRAS Proto-Oncogene, GTPase	Protein Coding	7.07	DISEASES inferred ¹⁵
4	MLANA	Melan-A	Protein Coding	6.97	DISEASES inferred ¹⁵
5	GNA11	G Protein Subunit Alpha 11	Protein Coding	6.87	DISEASES inferred ¹⁵
6	GNAQ	G Protein Subunit Alpha Q	Protein Coding	6.76	DISEASES inferred ¹⁵
7	MIR4427	MicroRNA 4427	RNA Gene	6.75	DISEASES inferred ¹⁵
8	IFNA2	Interferon Alpha 2	Protein Coding	6.52	DISEASES inferred ¹⁵
9	MIR8078	MicroRNA 8078	RNA Gene	6.51	DISEASES inferred ¹⁵
10	MIR302D	MicroRNA 302d	RNA Gene	6.4	DISEASES inferred ¹⁵
11	EIF1AX	Eukaryotic Translation Initiation Factor 1A X-Linked	Protein Coding	6.38	DISEASES inferred ¹⁵
12	MIR4654	MicroRNA 4654	RNA Gene	6.34	DISEASES inferred ¹⁵
13	MIR6084	MicroRNA 6084	RNA Gene	6.31	DISEASES inferred ¹⁵
14	HRAS	HRas Proto-Oncogene, GTPase	Protein Coding	6.18	DISEASES inferred ¹⁵
15	MIR4528	MicroRNA 4528	RNA Gene	6.17	DISEASES inferred ¹⁵
16	MIR4278	MicroRNA 4278	RNA Gene	6.13	DISEASES inferred ¹⁵

Sources

Variations for Malignant Conjunctival Melanoma

Sources

Expression for Malignant Conjunctival Melanoma

Search GEO for disease gene expression data for Malignant Conjunctival Melanoma.

Sources

Pathways for Malignant Conjunctival Melanoma

Pathways related to Malignant Conjunctival Melanoma according to GeneCards Suite gene sharing:

(show all 26)

#	Super pathways	Score	Top Affiliating Genes
1	Toll-like Receptor Signaling Pathway ³⁶ ¹ Show member pathways Chagas disease ³⁶ Hepatitis B ³⁶ Hepatitis C ³⁶ Regulation of toll-like receptor signaling pathway ¹	12.88	NRAS IFNA2 HRAS GNAQ GNA11
2	Development Angiotensin activation of ERK ²³ Show member pathways Cell adhesion Integrin inside-out signaling ²³ Development ACM2 and ACM4 activation of ERK ²³ Development Angiotensin signaling via PYK2 ²³ Development EDNRB signaling ²³ Development EPO-induced MAPK pathway ²³ Development G-Proteins mediated regulation MARK-ERK signaling ²³ Signal transduction IP3 signaling ²³	12.65	NRAS HRAS GNAQ GNA11
3	Human cytomegalovirus infection ³⁶ Show member pathways Human immunodeficiency virus 1 infection ³⁶ Kaposi sarcoma-associated herpesvirus infection ³⁶	12.65	NRAS IFNA2 HRAS GNAQ GNA11
4	Pathways in cancer ³⁶	12.53	NRAS IFNA2 HRAS GNAQ GNA11
5	Relaxin signaling pathway ³⁶ Show member pathways Estrogen signaling pathway ³⁶ Growth hormone synthesis, secretion and action ³⁶ Relaxin receptors ⁶⁵	12.51	NRAS HRAS GNAQ GNA11
6	Development Endothelin-1/EDNRA signaling ²³ Show member pathways Cytoskeleton remodeling FAK signaling ²³ Development Endothelin-1/EDNRA transactivation of EGFR ²³ GnRH signaling pathway ³⁶ Inflammatory mediator regulation of TRP channels ³⁶	12.4	NRAS HRAS GNAQ GNA11
7	Oxytocin signaling pathway ³⁶ Show member pathways Vascular smooth muscle contraction ³⁶	12.19	NRAS HRAS GNAQ GNA11
8	Apelin signaling pathway ³⁶	11.92	NRAS HRAS GNAQ
9	Development A2B receptor- action via G-protein alpha s ²³ Show member pathways Development A2A receptor signaling ²³	11.85	HRAS GNAQ GNA11
10	Translation Translation regulation by Alpha-1 adrenergic receptors ²³ Show member pathways Development Activation of ERK by Alpha-1 adrenergic receptors ²³	11.83	HRAS GNAQ GNA11
11	Sphingolipid signaling pathway ³⁶	11.82	NRAS HRAS GNAQ
12	Serotonergic synapse ³⁶	11.79	NRAS HRAS GNAQ
13	MAP Kinase Signaling ⁴	11.77	NRAS HRAS GNAQ
14	Long-term potentiation ³⁶ Show member pathways Common Pathways Underlying Drug Addiction ¹	11.74	NRAS HRAS GNAQ
15	UVA-Induced MAPK Signaling ⁶³ Show member pathways UVB-Induced MAPK Signaling ⁶³	11.73	NRAS HRAS GNAQ GNA11
16	G-protein signaling_RhoA regulation pathway ²³	11.49	NRAS HRAS GNAQ GNA11
17	Gap junction ³⁶	11.4	NRAS HRAS GNAQ GNA11
18	LPA receptor mediated events ¹	11.36	HRAS GNAQ GNA11
19	GnRH secretion ³⁶	11.06	NRAS HRAS GNAQ GNA11
20	EGFR Transactivation by Gastrin ⁶⁵ Show member pathways EGFR-dependent Endothelin signaling events ¹ SHC-related events triggered by IGF1R ⁶⁵	11.04	NRAS HRAS
21	MNAR-PELP1 and Estrogen Receptor Interaction ⁶³	10.98	NRAS HRAS
22	CD209 (DC-SIGN) signaling ⁶⁵	10.96	NRAS HRAS
23	Free fatty acids regulate insulin secretion ⁶⁵ Show member pathways Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion ⁶⁵	10.75	GNAQ GNA11
24	Serotonin Receptor 2 and ELK-SRF/GATA4 signaling ¹	10.73	NRAS HRAS GNAQ
25	Long-term depression ³⁶	10.7	NRAS HRAS GNAQ GNA11
26	p38MAPK events ⁶⁵	10.59	NRAS HRAS

Sources

GO Terms for Malignant Conjunctival Melanoma

Biological processes related to Malignant Conjunctival Melanoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	action potential	GO:0001508	9.26	GNA11 GNAQ
2	G protein-coupled acetylcholine receptor signaling pathway	GO:0007213	9.16	GNAQ GNA11
3	phototransduction, visible light	GO:0007603	8.96	GNAQ GNA11
4	entrainment of circadian clock	GO:0009649	8.62	GNAQ GNA11

Molecular functions related to Malignant Conjunctival Melanoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	GTP binding	GO:0005525	9.62	NRAS HRAS GNAQ GNA11
2	G-protein beta/gamma-subunit complex binding	GO:0031683	9.26	GNAQ GNA11
3	GTPase activity	GO:0003924	9.26	NRAS HRAS GNAQ GNA11
4	guanyl nucleotide binding	GO:0019001	9.16	GNAQ GNA11
5	type 2A serotonin receptor binding	GO:0031826	8.62	GNAQ GNA11

Sources

Sources for Malignant Conjunctival Melanoma

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GARD

²¹ GeneAnalytics

²² GeneCards

²³ GeneGo (Thomson Reuters)

²⁴ GeneHancer via GeneCards

²⁵ GeneReviews

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HMDB

³¹ HPO

³² ICD10

³³ ICD10 via Orphanet

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ KEGG

³⁷ LifeMap

³⁸ LncRNADisease

³⁹ LOVD

⁴⁰ MalaCards

⁴¹ MedGen

⁴² MedlinePlus

⁴³ MedlinePlus Genetics

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NINDS

⁵⁴ Novoseek

⁵⁵ Novus Biologicals

⁵⁶ OMIM via Orphanet

⁵⁷ OMIM® (Updated 05-Mar-2021)

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubMed

⁶² PubMed Health

⁶³ QIAGEN

⁶⁴ R&D Systems

⁶⁵ Reactome

⁶⁶ Sino Biological

⁶⁷ SNOMED-CT

⁶⁸ SNOMED-CT via HPO

⁶⁹ TGDB

⁷⁰ Tocris

⁷¹ UMLS

⁷² UMLS via Orphanet

⁷³ UniProtKB/Swiss-Prot

⁷⁴ Wikipedia